Agile Therapeutics, Inc. (AGRX) is focused on fulfilling women’s unmet health needs. It offers various contraceptive options to women. The company’s product line includes Twirla transdermal system.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
AGRX stock price during the regular trading of March 29, 2022, was $0.25 with a slight decline of 0.08%. Its price rocketed higher as of the writing in the premarket trading on March 30, 2022, by 28.18%.
AGRX: Events and Happenings
On March 14, 2022, AGRX updated on the closure of already announced registered direct offering to sell 2,425 shares of convertible preferred stock and warrants for the acquisition of approximately 24,250,000 common stock shares and warrants for the acquisition of approximately 24,250,000 common stock shares with an institutional investor. The per-share price of the preferred stock is $1,000 and a per-share conversion price of $0.20. The warrants have a per-share exercise price of $0.26. The net proceeds resulting from the direct offering are worth $4.85 million.
On March 11, 2022, AGRX reported its Executive management to present at the following investor conferences.
- Oppenheimer’s Virtual 32ndAnnual Healthcare Conference held on March 17, and
- Maxim Group and M-Vest Virtual 2022 Growth Conference held March 28, 2022.
On March 07, 2022, AGRX informed the press regarding the issuance of its Q4 2021 and full fiscal year financial statement on March 30, 2022, along with hosting a conference call. The company will also provide commercial updates on Twirla.
AGRX: Key Financials
AGRX issued its unaudited Q3 2021 financials on November 2, 2021, for the three months ended September 30, 2021. Some notable highlights are discussed here.
The company posted net revenues of $1.3 million during the third quarter of 2021 in comparison to nil revenue during the corresponding quarter in 2020. The company’s net revenues surged by 100% YoY and it missed the revenue estimations by $175.2 thousand.
Per-share basic and diluted net loss during the third quarter of 2021 was $16.8 million or $0.18 corresponding to $15.5 million or $0.18 during the comparable period of 2020. The company’s net loss increased over the year and it surpassed the EPS expectations by $0.01.
AGRX stock was downplayed by 86% in the last year. Its stock price is leaping forward in Wednesday’s premarket trading as the company is gearing for the Financial statement release for the fourth quarter of 2021. The financial outlook for Q4 2021 is $1.51 million in revenue and -$0.15 EPS with improvements from the past year.